Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Short term Debt (2016 - 2017)

Historic Short term Debt for Jaguar Health (JAGX) over the last 3 years, with Q4 2017 value amounting to $1.6 million.

  • Jaguar Health's Short term Debt fell 1617.1% to $1.6 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.6 million, marking a year-over-year decrease of 1617.1%. This contributed to the annual value of $1.6 million for FY2017, which is 1617.1% down from last year.
  • Per Jaguar Health's latest filing, its Short term Debt stood at $1.6 million for Q4 2017, which was down 1617.1% from $1.8 million recorded in Q3 2017.
  • Jaguar Health's Short term Debt's 5-year high stood at $2.1 million during Q1 2016, with a 5-year trough of $21244.0 in Q1 2015.
  • Its 3-year average for Short term Debt is $1.6 million, with a median of $1.8 million in 2017.
  • Per our database at Business Quant, Jaguar Health's Short term Debt surged by 987801.73% in 2016 and then crashed by 1617.1% in 2017.
  • Quarter analysis of 3 years shows Jaguar Health's Short term Debt stood at $1.7 million in 2015, then grew by 12.4% to $1.9 million in 2016, then decreased by 16.17% to $1.6 million in 2017.
  • Its Short term Debt was $1.6 million in Q4 2017, compared to $1.8 million in Q3 2017 and $2.1 million in Q2 2017.